Skip to main content
Journal cover image

Risks and consequences of chemotherapy-induced neutropenia.

Publication ,  Journal Article
Lyman, GH
Published in: Clin Cornerstone
2006

Neutropenia represents a major dose-limiting toxicity of chemotherapy and is associated with an increased risk of infection, impaired patient quality of life, and interference with the delivery of full-dose chemotherapy. These complications increase not only morbidity and mortality associated with cancer treatment but also the overall cost of care for cancer patients. Conversely, chemotherapy-induced neutropenia as a surrogate for delivered dose intensity has been associated with improved cancer survival. Administration of myeloid growth factors, such as filgrastim and pegfilgrastim, reduces the risk for neutropenic complications and facilitates the delivery of full-dose chemotherapy. There is an ongoing effort to identify patients at increased risk for developing neutropenic complications who would likely benefit from preemptive myeloid growth factor therapy. Appropriate use of myeloid growth factors is associated with reduced neutropenic complications, improved patient quality of life, and potentially improved disease control and long-term survival.

Duke Scholars

Published In

Clin Cornerstone

DOI

ISSN

1098-3597

Publication Date

2006

Volume

8 Suppl 5

Start / End Page

S12 / S18

Location

United States

Related Subject Headings

  • Risk Factors
  • Practice Guidelines as Topic
  • Neutropenia
  • Humans
  • General & Internal Medicine
  • Colony-Stimulating Factors
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H. (2006). Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone, 8 Suppl 5, S12–S18. https://doi.org/10.1016/s1098-3597(06)80054-2
Lyman, Gary H. “Risks and consequences of chemotherapy-induced neutropenia.Clin Cornerstone 8 Suppl 5 (2006): S12–18. https://doi.org/10.1016/s1098-3597(06)80054-2.
Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006;8 Suppl 5:S12–8.
Lyman, Gary H. “Risks and consequences of chemotherapy-induced neutropenia.Clin Cornerstone, vol. 8 Suppl 5, 2006, pp. S12–18. Pubmed, doi:10.1016/s1098-3597(06)80054-2.
Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006;8 Suppl 5:S12–S18.
Journal cover image

Published In

Clin Cornerstone

DOI

ISSN

1098-3597

Publication Date

2006

Volume

8 Suppl 5

Start / End Page

S12 / S18

Location

United States

Related Subject Headings

  • Risk Factors
  • Practice Guidelines as Topic
  • Neutropenia
  • Humans
  • General & Internal Medicine
  • Colony-Stimulating Factors
  • Antineoplastic Agents